Effectiveness of the Lorodent Probiotic Lozenge in Reducing Plaque and S. Mutans Levels in Orthodontic Patients: a Randomized, Double-blind, Placebo-controlled Trial

Background/Objectives: To determine the efficacy of the Lorodent probiotic complex at reducing plaque accumulation and Streptococcus mutans levels in adolescent orthodontic patients. Methods: 60 adolescent orthodontic patients were randomized in a double-blind, parallel-group, placebo-controlled trial to receive either the Lorodent probiotic or placebo lozenge orally every day for a 28-day administration period. Plaque scores, supragingival plaque samples and saliva samples were assessed over a total of 56 days. Results: Participants receiving the placebo lozenge had a greater improvement in plaque scores compared to those receiving the Lorodent probiotic lozenge. There were no significant changes in S. mutans and total lactobacilli levels between the probiotic and placebo groups. Lozenge consumption compliance was over 90% and no adverse events were observed in the probiotic group. Conclusions: The Lorodent probiotic lozenge did not decrease plaque or S. mutans levels in adolescent patients undergoing fixed orthodontic appliance treatment. Funding: Ontario Centres of Excellence.M.Sc